

- ~~—and wherein the amount of the diphtheria toxoid used as an immunogenic antigen of~~
Corynebacterium diphtheriae immunogenic antigen ~~of is~~ between 4-16 Lf per ml.
2. (Amended) The vaccine as claimed in claim 1, ~~characterized in that~~ wherein the amount of diphtheria ~~toxoid~~ immunogenic antigen is about 10 Lf per ml.
3. (Amended) The vaccine as claimed in claim 1 ~~or 2, in which~~ wherein the amount of tetanus ~~toxoid~~ immunogenic antigen is about 20 Lf per ml.
4. (Amended) The vaccine as claimed in ~~any one of claims 1 to 3~~ claim 1, also ~~further~~ comprising at least one antigen ~~chosen~~ selected from the group consisting of *Bordetella pertussis*, hepatitis A and hepatitis B antigens.
9. (Amended) A pharmaceutical kit comprising at least 2 injectable doses of ~~a~~ the vaccine as claimed in ~~one of claims 1 to 4~~ claim 1.
10. A method for immunizing a human against at least ~~the~~ poliovirus, *Corynebacterium diphtheriae* and *Clostridium tetani*, the method comprising ~~the administration of a~~ administering to the person a vaccine as claimed in ~~any one of claims 1 to 4~~ claim 1.
11. (Amended) ~~A primary immunization~~ The method as claimed in claim 10, ~~in which~~ wherein the vaccine is administered via ~~the~~ deep subcutaneous or intramuscular ~~route~~ injection, ~~preferably via the intramuscular route in the deltoid region~~, in 3 doses of ~~said vaccine, preferably at 0.5 ml~~, the first two doses being administered 1 to 2 months apart, ~~and~~ and the third dose being administered 6 to 12 months after the injection of the second dose.